Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.CONCLUSIONSThese data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, DNL has been associated with hepatic and whole-body IR (glucose metabolism),24,25 suggesting that IR may accelerate hepatic DNL.25”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [25]
In the citing paper
“In a well-designed study by Smith et al. [50], the contribution of hepatic DNL to intrahepatic TG palmitate was 11%, 19%, and 38% in the lean, obese, and obese-MASLD groups, respectively.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
In the citing paper
“Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“First, the long (3-5 week) duration of D2O tracer administration in our study accounted for labelling of the liver TG pools that turn over slowly (12) and provided an integrated assessment of DNL during daily fasting and fed conditions over several weeks.”
BackgroundMethodResultInfluentialA new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 2×
“The initial daily energy content of the diet provided 75% of estimated energy requirements (54); subsequent meals and energy”
BackgroundMethodObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Self-citationNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Although the mechanism(s) responsible for the increase in hepatic DNL in people with NAFLD is not known, it is possible that increases in circulating insulin and glucose associated with hepatic and whole-body insulin resistance are involved in stimulating hepatic DNL because insulin and glucose activate SREBP-1c and C…”
Background
Research works printed but not linked: 2
- 10.1172/JCI22422 · DOI · Paper page
- 10.1016/S1097-2765(05)00010-9 · doi:10.1016/s1097-2765(05)00010-9 · Paper page
Cited by
Items 101–200 of 770
Theofilis, P., Vordoni, A., & Kalaitzidis, R. (2022) · Metabolites · doi:10.3390/metabo12121243 · Cited by 70
“Toxic metabolites such as diacylglycerol and ceramides can cause insulin resistance during DNL, resulting in a positive feedback loop in which insulin resistance encourages hepatic DNL and hepatic DNL promotes insulin resistance [35].”
BackgroundSkeletal muscle and MASLD: Mechanistic and clinical insights
Marjot, T., Armstrong, M. J., & Stine, J. G. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000711 · Cited by 84
“[57] In addition, myokine alterations secondary to insulin resistance may negatively impact liver histology and metabolic homeostasis.”
Beals, J. W., Smith, G. I., Shankaran, M., Fuchs, A., Schweitzer, G. G., Yoshino, J., Field, T., Matthews, M., Nyangau, E., Morozov, D., et al. (2021) · Hepatology · doi:10.1002/hep.31822 · Cited by 59
Self-citationEnvisioning how to advance the MASH field
Allen, A. M., Younossi, Z. M., Diehl, A. M., Charlton, M., & Lazarus, J. V. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00938-9 · Cited by 69
The role of adipose tissue dysfunction in hepatic insulin resistance and T2D
Sancar, G., & Birkenfeld, A. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0115 · Cited by 80
“…and associated hepatic insulin resistance, lipid synthesis from FFAs is responsible for 60% of the TAG stored in the liver (Donnelly et al. 2005, Smith et al. 2020) Moreover, increased lipogenesis observed in patients with fatty liver is driven by the lipogenic substrate availability rather…”
BackgroundCeja-Galicia, Z. A., Cespedes-Acuña, C. L. A., & El-Hafidi, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020788 · Cited by 61
Guerra, S., Mocciaro, G., & Gastaldelli, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13695 · Cited by 65
Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets
Katz, L. S., Baumel-Alterzon, S., Scott, D. K., & Herman, M. A. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100623 · Cited by 62
He, Z., Li, X., Yang, H., Wu, P., Wang, S., Cao, D., Guo, X. C., Xu, Z., Gao, J., Zhang, W., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.745609 · Cited by 90
The adipocyte supersystem of insulin and cAMP signaling
Guilherme, A., Rowland, L. A., Wang, H., & Czech, M. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.07.009 · Cited by 63
Zhu, C., Huai, Q., Zhang, X., Dai, H., Li, X., & Wang, H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.78525 · Cited by 69
“The exact mechanism that drives de novo lipogenesis in NAFLD remains unknown, but activation of SREBP-1c and ChREBP due to increased circulating insulin and glucose in the context of whole-body insulin resistance has been suggested as a central driver [37].”
BackgroundDu, F., Huang, R., Lin, D., Wang, Y., Yang, X., Huang, X., Zheng, B., Chen, Z., Huang, Y., Wang, X., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.611323 · Cited by 62
“What’s more, we found that RSV can affect the insulin signaling pathway and the changes is associated with altered gut microbiota, previous findings showed that changes in the insulin signaling pathway can affect liver steatosis by altering the lipid metabolism process (Leavens and Birnbaum, 2011; Smith et al., 2020),…”
BackgroundDe novo lipogenesis fuels adipocyte autophagosome and lysosome membrane dynamics
Rowland, L. A., Guilherme, A., Henriques, F. D. S., DiMarzio, C., Munroe, S., Wetoska, N., Kelly, M., Reddig, K. R., Hendricks, G. M., Pan, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37016-8 · Cited by 68
Frankowski, R., Kobierecki, M., Wittczak, A., Różycka-Kosmalska, M., Pietras, T., Sipowicz, K., & Kosmalski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119677 · Cited by 58
Aquaporins in insulin resistance and diabetes: More than channels!
Galli, M., Hameed, A., Żbikowski, A., & Zabielski, P. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102027 · Cited by 62
“insulin is known also to promote lipogenesis in the liver [77].”
BackgroundThe role of hepatic lipid composition in obesity‐related metabolic disease
Willis, S. A., Bawden, S., Malaikah, S., Sargeant, J. A., Stensel, D. J., Aithal, G. P., & King, J. A. (2021) · Liver International · doi:10.1111/liv.15059 · Cited by 69
Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review
Coronati, M., Baratta, F., Pastori, D., Ferro, D., Angelico, F., & Ben, M. D. (2022) · Nutrients · doi:10.3390/nu14061127 · Cited by 68
“In the liver, fructose supports de novo lipogenesis (DNL), induces endoplasmic reticulum stress and inflammation, leading to a reduction in hepatocytes’ insulin sensitivity [62,63].”
BackgroundReprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis
Rui, L., & Lin, J. D. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062220-105200 · Cited by 56
Yang, S., Cao, S., Li, C., Zhang, J., Liu, C., Qiu, F., & Kang, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.913378 · Cited by 66
“Glucose and insulin stimulate hepatic de novo lipogenesis in individuals with NAFLD (Smith et al., 2020).”
BackgroundTian, S., Lei, Y., Zhao, F., Che, J., Wu, Y.-H., Lei, P., Kang, Y. E., & Shan, Y. (2024) · Food & Function · doi:10.1039/d4fo01059k · Cited by 67
Cao, X., Wang, N., Yang, M. J., & Zhang, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146962 · Cited by 79
“Intrahepatic DNL inversely correlates with systemic insulin sensitivity and fuels TG storage [129].”
Hormonal regulation of metabolism—recent lessons learned from insulin and estrogen
Tao, Z., & Cheng, Z. (2023) · Clinical Science · doi:10.1042/cs20210519 · Cited by 75
Mocciaro, G., Allison, M., Jenkins, B., Azzu, V., Huang-Doran, I., Herrera-Marcos, L. V., Hall, Z., Murgia, A., Susan, D., Frontini, M., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101728 · Cited by 56
“1a,b), likely reflecting the known activation of DNL programs previously described in NAFLD [11,14,26,27].”
BackgroundHe, Y., Chen, X., Li, Y., Liang, Y., Hong, T., Yang, J., Cao, Z., Mai, H., Yao, J., Zhang, T., et al. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.05.017 · Cited by 63
Song, J., Ma, R., & Yin, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398265 · Cited by 61
Halabitska, I., Бабинец, Л. С., Oksenych, V., & Kamyshnyi, O. (2024) · Biomedicines · doi:10.3390/biomedicines12081630 · Cited by 60
“…and pro-inflammatory protein gene expression in the subcutaneous abdominal AT of individuals with metabolically unhealthy obesity compared to those with metabolically healthy obesity, it remains challenging to determine if this inflammation is a cause or effect of insulin resistance [31–33].”
BackgroundMichalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 76
“This process, known as hepatic de novo lipogenesis, generates toxic metabolites like glycerol and ceramides, perpetuating insulin resistance and creating a cycle that exacerbates hepatic steatosis [26].”
Beysen, C., Schroeder, P. E., Wu, E., Brevard, J. A., Ribadeneira, M. D., Lu, W., Dole, K., O’Reilly, T. E., Morrow, L., Hompesch, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14272 · Cited by 58
Self-citationBellanti, F., Buglio, A. L., Dobrakowski, M., Kasperczyk, A., Kasperczyk, S., Aich, P., Singh, S. P., Serviddio, G., & Vendemiale, G. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i26.3243 · Cited by 60
Diabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
Pathophysiology and treatment of prediabetes and type 2 diabetes in youth
Bacha, F., Hannon, T. S., Tosur, M., Pike, J. M., Butler, A., Tommerdahl, K. L., & Zeitler, P. S. (2024) · Diabetes Care · doi:10.2337/dci24-0029 · Cited by 57
Ezhilarasan, D. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155912 · Cited by 57
Mucinski, J. M., Salvador, A. F., Moore, M. P., Fordham, T. M., Anderson, J. M., Shryack, G. E., Cunningham, R. P., Lastra, G., Gaballah, A. H., Diaz‐Arias, A. A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.017 · Cited by 66
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Fouqueray, P., Bolze, S., Dubourg, J., Hallakou‐Bozec, S., Theurey, P., Grouin, J., Chevalier, C., Dagorn, P. G., Moller, D. E., & Cusi, K. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100474 · Cited by 57
“Of particular note, increased hepatic DNL is a substantial contributor to steatosis and has been estimated to account for up to 38% of excess liver fat content in obese NAFLD patients.(16) Importantly, the onset and progression of NAFLD-NASH are coupled with insulin resistance through several overlapping pathways invo…”
BackgroundZhao, R., Zhu, M., Zhou, S., Feng, W., & Chen, H. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00407 · Cited by 55
“DNL, accounting for 26% of hepatic triglyceride in human subjects (Smith et al., 2020), is increased in NAFLD patients compared with healthy (Shimano and Sato, 2017), suggesting the potential therapeutic strategy through inhibition of DNL for the treatment of NAFLD.”
BackgroundUehara, K., Sostre-Colón, J., Gavin, M., Santoleri, D., Leonard, K.-A., Jacobs, R. L., & Titchenell, P. M. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.015 · Cited by 50
Yu, X.-D., & Wang, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115157 · Cited by 56
Insulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
“Prominently, 25% to 30% of hepatic TAG is produced through DNL in individuals with NAFLD (77, 174, 297).”
Acetyl-CoA and Metabolite Fluxes Regulate White Adipose Tissue Expansion
Felix, J. B., Cox, A. R., & Hartig, S. M. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.008 · Cited by 62
Ferdous, S.-E., & Ferrell, J. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168731 · Cited by 60
“…IR and in fl ammation contribute to morbidity in patients with obesity, and in fl ammation is also considered to play a crucial role in the development of IR [12]. hepatic gluconeogenesis and glycolysis further provides substrates for de novo lipogenesis and thereby results in hepatic steatosis [15].”
BackgroundKang, H., You, H. J., Lee, G., Lee, S. H., Yoo, T., Choi, M., Joo, S. K., Park, J. H., Chang, M. S., Lee, D. H., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2078612 · Cited by 49
“GGT is inversely associated with insulin sensitivity,(47) and insulin resistance induces hepatic DNL in NAFLD.(9) In addition, Enterobacteriaceae play a central role in regulating DNL-associated genes by stimulating SREBF2 and inhibiting SIRT1 expression.”
BackgroundInfluentialHui, D., Liu, L., Azami, N. L. B., Song, J., Huang, Y., Xu, W., Wu, C., Xie, D., Jiang, Y., Bian, Y., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1107071 · Cited by 56
“Circulating insulin and glucose promotes de novo lipogenesis (DNL) through activation of sterol regulating element binding protein 1c (SREBP1c) and the carbohydrate response element binding protein (ChREBP) (17, 18).”
BackgroundGudan, A., Kozłowska‐Petriczko, K., Wunsch, E., Bodnarczuk, T., & Stachowska, E. (2023) · Nutrients · doi:10.3390/nu15061323 · Cited by 62
“and hyperglycemia are diagnosed among patients with NAFLD [33,34]; therefore, intestinal barrier disruption and intestinal permeability may equally result from these mechanisms.”
BackgroundSex, Nutrition, and NAFLD: Relevance of Environmental Pollution
Dolce, A., & Torre, S. D. (2023) · Nutrients · doi:10.3390/nu15102335 · Cited by 51
“In particular, overnutrition and poor dietary habits trigger insulin resistance (IR) and increase adiposity, favoring lipid deposition in the liver [5,21].”
BackgroundSohn, W., Lee, Y., Kim, S. S., Kim, J. H., Jin, Y., Kim, G., Sung, P. S., Yoo, J., Chang, Y. W., Lee, E. J., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0045 · Cited by 76
Chen, H. (2020) · Liver Research · doi:10.1016/j.livres.2020.02.004 · Cited by 54
Perspectives on youth‐onset nonalcoholic fatty liver disease
Castillo‐Leon, E., Cioffi, C. E., & Vos, M. B. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.184 · Cited by 47
“39 This role of DNL in the pathogenesis NAFLD may have increased relevance for children, who tend to consume more fructose compared to adults, 40 and since fructose has been shown to induce DNL in humans.”
BackgroundWang, W., Zhong, X., & Guo, J. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4947 · Cited by 54
“The direct contributors to excess lipid storage in the liver include increased circulating NEFAs, accelerated de novo lipogenesis, overloaded dietary fat and inadequate lipid oxida‐ tion (64,65,134,138).”
BackgroundLean nonalcoholic fatty liver disease and sarcopenia
Chen, M., Cao, Y. Y., Ji, G., & Zhang, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1217249 · Cited by 54
“Insulin resistance leads to inhibition of b-oxidation, increased gluconeogenesis, increased expression of sterol regulatory element binding protein-1c (SREBP1c), as well as increased production of FFAs, leading to accumulation of triglycerides in skeletal muscle and liver, and the long-term level of inflammation might…”
BackgroundChen, V. L., Kuppa, A., Oliveri, A., Chen, Y., Ponnandy, P., Patel, P. B., Palmer, N. D., & Speliotes, E. K. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186424 · Cited by 64
“This in turn may promote MASLD via increased release of fatty acids from adipose tissue (89, 90) or increased hepatic de novo lipogenesis in liver (91).”
Linking liver metabolic and vascular disease via bile acid signaling
Fiorucci, S., & Distrutti, E. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.10.005 · Cited by 49
Detangling the interrelations between MAFLD, insulin resistance, and key hormones
Pal, S. C., Eslam, M., & Méndez‐Sánchez, N. (2022) · HORMONES · doi:10.1007/s42000-022-00391-w · Cited by 49
Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD
Kumar, S. R., Wong, R., Newberry, C. A., Yeung, M., Peña, J. M., & Sharaiha, R. Z. (2021) · Hepatology · doi:10.1002/hep.32081 · Cited by 45
Gangopadhyay, A., Ibrahim, R., Theberge, K., May, M. A., & Houseknecht, K. L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1042442 · Cited by 56
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Domingues, I., Leclercq, I. A., & Beloqui, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.040 · Cited by 46
The physiology of MASLD: molecular pathways between liver and adipose tissues
Lee, W., Kipp, Z. A., Bates, E. A., Pauss, S. N., Martinez, G. J., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20257571 · Cited by 56
“The overactivation of the DNL pathway can manifest in several diseases, including MASLD [121], which occurs with hepatic insulin resistance [75].”
InfluentialProtective effects of p-coumaric acid against high-fat diet-induced metabolic dysregulation in mice
Yoon, D. S., Cho, S. Y., Yoon, H. J., Kim, S. R., & Jung, U. J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111969 · Cited by 47
Amiri, P., Arefhosseini, S., Bakhshimoghaddam, F., Gurvan, H. J., & Hosseini, S. A. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1037696 · Cited by 49
“Targeting IRdependent lipogenesis could be a goal for NAFLD (61, 62).”
BackgroundUpregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice
Yao, Z., Gong, Y., Chen, W., Shao, S., Song, Y., Guo, H., Li, Q., Liu, S., Wang, X., Zhang, Z., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00896-7 · Cited by 48
“Smith et al. observed human hepatic DNL showed a negative correlation with hepatic and whole-body insulin sensitivity, but positively correlated with plasma glucose/insulin concentrations 16 .”
BackgroundThe signaling pathways in obesity‐related complications
Chandrasekaran, P., & Weiskirchen, R. (2024) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.12039 · Cited by 55
Leptin decreases de novo lipogenesis in patients with lipodystrophy
Baykal, A. P., Parks, E. J., Shamburek, R. D., Syed‐Abdul, M. M., Chacko, S. K., Cochran, E. K., Startzell, M. S., Gharib, A. M., Ouwerkerk, R., Abd‐Elmoniem, K. Z., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137180 · Cited by 48
“due to the relatively short duration of deuterium labeling of body water (11 hours) (16) — although the over-”
BackgroundResultInsulin Clearance in Obesity and Type 2 Diabetes
Koh, H. E., Cao, C., & Mittendorfer, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020596 · Cited by 236
“Non-alcoholic fatty liver disease (NAFLD) is common in people with obesity [139] and associated with insulin resistance [168].”
BackgroundMenopause modulates the circulating metabolome: evidence from a prospective cohort study
Karppinen, J. E., Törmäkangas, T., Kujala, U. M., Sipilä, S., Laukkanen, J. A., Aukee, P., Kovanen, V., & Laakkonen, E. K. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac060 · Cited by 54
The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease
Xu, H., & Wang, L. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.792667 · Cited by 45
Lipedema: Progress, Challenges, and the Road Ahead
Cifarelli, V. (2025) · Obesity Reviews · doi:10.1111/obr.13953 · Cited by 59
(−)-Epicatechin and the comorbidities of obesity
Cremonini, E., Iglesias, D. E., Kang, J., Lombardo, G. E., Mostofinejad, Z., Wang, Z., Zhu, W., & Oteiza, P. I. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108505 · Cited by 44
“The associated insulin resistance also contributes to NAFLD pathogenesis by promoting de novo lipogenesis [159].”
BackgroundMitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases
Dabravolski, S. A., Bezsonov, E. E., Baig, M. S., Попкова, Т. В., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136949 · Cited by 45
“An imbalance between imported/exported and synthesized/processed FAs results in hepatic lipid accumulation, hepatosteatosis and IR, which is further stimulating de novo hepatic lipogenesis making this vicious cycle complete [53].”
BackgroundGart, E., van Duyvenvoorde, W., Caspers, M. P. M., van Trigt, N., Snabel, J. M., Menke, A. L., Keijer, J., Salic, K., Morrison, M. C., & Kleemann, R. (2022) · The FASEB Journal · doi:10.1096/fj.202200111r · Cited by 44
Hughey, C. C., Puchalska, P., & Crawford, P. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159209 · Cited by 58
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 48
“As previously described, NAFLD is associated with increased insulin resistance [13,28] which is itself associated with cardiovascular disease [190].”
BackgroundMeasurement of lipogenic flux by deuterium resolved mass spectrometry
Fu, X., Deja, S., Fletcher, J. A., Anderson, N. N., MIZERSKA, M. N., do Vale, G. D., Browning, J. D., Horton, J. D., McDonald, J. G., Mitsche, M. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23958-4 · Cited by 43
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Semmler, G., Datz, C., & Trauner, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0364 · Cited by 46
Surveillance of the liver in type 2 diabetes: important but unfeasible?
Qadri, S. U., & Yki‐Järvinen, H. (2024) · Diabetologia · doi:10.1007/s00125-024-06087-7 · Cited by 47
“…in hepatocytes) results from an influx of excess fatty acids into the liver from three main sources: (1) circulating fatty acids released through peripheral lipolysis; (2) de novo synthesis of fatty acids in the liver from lipogenic pre-cursors; and (3) dietary intake of fatty acids [14–16].”
BackgroundThe regulatory role of PI3K in ageing-related diseases
Liu, Y., Liu, Q., Zhang, Z., Yang, Y., Zhou, Y., Yan, H., Wang, X. L., Li, X., Zhao, J., Hu, J., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101963 · Cited by 40
Zhu, Z., Zhang, X., Pan, Q., Zhang, L., & Chai, J. (2023) · Liver Research · doi:10.1016/j.livres.2023.11.003 · Cited by 38
“33 DNL may produce toxic metabolites like diacylglycerol and ceramides, potentially leading to insulin resistance.”
InfluentialConcise review of lipidomics in nonalcoholic fatty liver disease
Béland‐Bonenfant, S., Rouland, A., Petit, J., & Vergès, B. L. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101432 · Cited by 38
The role of autophagy in the treatment of type II diabetes and its complications: a review
Zhao, X., Bie, L., Pang, D.-R., Li, X., Yang, L., Chen, D., Wang, Y.-R., & Gao, Y. J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1228045 · Cited by 41
“These two pathological states of T2DM and NAFLD seem to be dif fi cult to say who is the cause and who is the effect, but they share similar complex pathophysiological mechanisms, such as insulin resistance, chronic hyperglycemia, lipotoxicity, low-grade in fl ammation and increased oxidative stress, and both act synerg…”
BackgroundInfluentialTantu, M. T., Farhana, F. Z., Haque, F., Koo, K. M., Qiao, L., Ross, A. G., & Shiddiky, M. J. A. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00030-2 · Cited by 57
“In insulin resistance, disrupted signalling promotes DNL through transcription factors like sterol regulatory element-binding protein 1c (SREBP-1c) and carbohydrate response element binding protein (ChREBP), leading to steatosis 27 .”
Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD
Wang, S., Zhu, Q., Liang, G., Franks, T., Boucher, M., Bence, K. K., Lu, M., Castorena, C. M., Zhao, S., Elmquist, J. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152242 · Cited by 39
“Recent studies suggest that up to 38% of the fatty acids in TGs in liver are derived from de novo lipogenesis, while approximately 15% come from diet and the remaining from free fatty acids in the blood (6).”
BackgroundHepatocyte leukotriene B4 receptor 1 promotes NAFLD development in obesity
Liu, X., Wang, K., Wang, L., Kong, L., Hou, S., Wan, Y., Ma, C., Chen, J., Xing, X., Xing, C., et al. (2022) · Hepatology · doi:10.1002/hep.32708 · Cited by 45
“[5] Similarly, a study showed that the contribution of hepatic DNL to the increase in intrahepatic TG was 11%, 19%, and 38% in the lean, obese without fatty liver, and obese‐NAFLD groups, respectively.[6] These clinical data collectively indicate that failure to regulate DNL is a central feature of liver lipid accumul…”
Lawitz, E., Li, K. W., Nyangau, E., Field, T., Chuang, J.-C., Billin, A. N., Wang, L., Wang, Y., Huss, R. S., Chung, C., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100250 · Cited by 42
“We have shown elsewhere (27) that DNL from adipose-derived fatty acids contributes minimally to DNL that is measured in plasma palmitate even during a long-term labeling period of 3–5 weeks duration, so the labeled slow turnover pool is not derived from adipose tissue, but must derive from TG in the liver.”
BackgroundInfluentialSelf-citationDashti, Z. J. S., Yousefi, Z., Kiani, P., Taghizadeh, M., Maleki, M. H., Borji, M., Vakili, O., & Shafiee, S. M. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155811 · Cited by 38
Li, M., Cui, M., Li, G., Liu, Y., Xu, Y., Eftekhar, S. P., & Ala, M. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2266-1503 · Cited by 37
“Interestingly, Smith et al. un-covered that hepatic de novo lipogenesis in response to intrahepatic triglyceride was 11 %, 19 %, and 38 % in lean, obese, and obese-NAFLD individuals, respectively [33].”
Rauckhorst, A. J., Sheldon, R. D., Pape, D. J., Ahmed, A., Falls-Hubert, K. C., Merrill, R. A., Brown, R. F., Deshmukh, K., Vallim, T., Deja, S., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.10.013 · Cited by 45
Park, G. S. H., Jung, S., Wellen, K. E., & Jang, C. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00614-x · Cited by 39
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome
Michelotti, A., de Scordilli, M., Palmero, L., Guardascione, M., Masala, M., Roncato, R., Foltran, L., Ongaro, E., & Puglisi, F. (2021) · Cells · doi:10.3390/cells10082034 · Cited by 48
“Hepatic de novo lipogenesis is regulated by several transcription factors, such as sterol regulatory element-binding protein-1 (SREBP-1), carbohydrate response element-binding protein (ChREBP), and peroxisome proliferator-activated receptor (PPAR)-γ, which are regulated by insulin levels and are involved in cell chole…”
BackgroundOuyang, S., Zhuo, S., Yang, M., Zhu, T., Yu, S., Li, Y., Ying, H., & Le, Y. (2024) · Advanced Science · doi:10.1002/advs.202401311 · Cited by 48
Wang, S., Yin, J., Liu, Z., Liu, X., Tian, G., Xin, X., Qin, Y., & Feng, X. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123211 · Cited by 46
Hoozemans, J., de Brauw, M., Nieuwdorp, M., & Gerdes, V. E. A. (2021) · Metabolites · doi:10.3390/metabo11060353 · Cited by 39
“Insulin resistance is associated with increased hepatic de novo lipogenesis, contributing to fatty liver disease [74].”
BackgroundRetinoids in the Pathogenesis and Treatment of Liver Diseases
Melis, M., Tang, X., Trasino, S. E., & Gudas, L. J. (2022) · Nutrients · doi:10.3390/nu14071456 · Cited by 41
“De novo fatty acid synthesis converts non-lipid precursors into fatty acids, and de novo fatty acid synthesis can contribute almost 40% of intrahepatic triglycerides in subjects with NAFLD [80].”
BackgroundBacteroides and NAFLD: pathophysiology and therapy
Zhang, J., Zhou, J., He, Z., & Li, H. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1288856 · Cited by 44
Hewage, S. M., Prashar, S., Karmin, O., & Siow, Y. L. (2021) · Antioxidants · doi:10.3390/antiox10040565 · Cited by 39
“Elevation of plasma and hepatic lipids induces insulin resistance, which stimulates hepatic de novo lipogenesis, one of the mechanisms for hepatic lipid accumulation in NAFLD [10].”
BackgroundInhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes
Chen, L., Wu, N., Kennedy, L. L., Francis, H., Ceci, L., Zhou, T., Samala, N. R., Kyritsi, K., Wu, C., Sybenga, A. B., et al. (2021) · Hepatology · doi:10.1002/hep.31871 · Cited by 35
“(10) Lipogenesis is regulated by acetylCoA being converted to malonyl- CoA by acetylCoA carboxylase, and malonyl- CoA is then converted to palmitate by fatty acid synthase (FASN).(11) Elevated lipogenesis, in combination with excess adipose fatty acid release, is a significant contributor to NAFLD.”
BackgroundBaratta, F., D’Erasmo, L., Bini, S., Pastori, D., Angelico, F., Ben, M. D., Arca, M., & Costanzo, A. D. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.011 · Cited by 36
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Filipović, B. F., Marjanovic-Haljilji, M., Mijac, D. D., Lukić, S., Kapor, S., Kapor, S., Starčević, A., Popovic, D. D., & Djoković, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110573 · Cited by 37
“IR increases DNL IR starts hepatic de novo lipogenesis (DNL) and impaired fa tt y acid (FA) transport. in the liver [10,11].”
Desjardins, E. M., Wu, J., Lavoie, D. C. T., Ahmadi, E., Townsend, L. K., Morrow, M. R., Wang, D., Tsakiridis, E. E., Batchuluun, B., Fayyazi, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101193 · Cited by 33
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 42
“This, so-called de novo lipogenesis of the liver leads to the production of toxic metabolites, like glycerol and ceramides that in turn lead to insulin resistance and a vicious cycle that further aggregates hepatic steatosis [223].”
BackgroundRabbani, N., & Thornalley, P. J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1268308 · Cited by 44
Association between TyG index trajectory and new-onset lean NAFLD: a longitudinal study
Liu, H., Chen, J., Qin, Q., Su, Y., Wang, Y., Li, J., & Ding, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1321922 · Cited by 37
Metadata
- Authors
- Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., Sirlin, C. B., Talukdar, S., Hellerstein, M. K., & Klein, S.
- Affiliations
- Washington University in St. Louis (US)
- University of California, Berkeley (US)
- University of California San Diego (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Klein, Samuel
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1453-1460
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269561
- OpenAlex
- W2993862932
- Cited by
- 771
- References
- 65
- Citations by year
- 2026: 121 · 2025: 136 · 2024: 153 · 2023: 123 · 2022: 104 · 2021: 92 · 2020: 40
- FWCI
- 44.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (DK56341,DK20579,DK52574,RR024992)
- College of Natural Resources, University of California at Berkeley (N/A)
- Pershing Square Foundation (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, hepatic de novo lipogenesis, insulin resistance, intrahepatic triglyceride, hepatic insulin sensitivity, weight loss, obesity, hepatic steatosis, plasma glucose, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Insulin, Insulin Resistance, Liver, Male, Triglycerides, Palmitic Acid, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.